Advanced Small Cell Lung Carcinoma
Conditions
Keywords
Small-cell Lung Cancer, Epirubicin, Paclitaxel, Cerebral Efficacy, Real-life
Brief summary
Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease. Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment, data is lacking more particularly about specific response on brain metastasis. In this retrospective multicentric observational study in real life conditions, we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (age ≥18 years) * Histologically or cytologically SCLC diagnosis * Treated with epirubicin-paclitaxel doublet between January 2010 and December 2020
Exclusion criteria
* Opposition to participate registered * Patients under legal protection * Patients afflicted by another subtype of lung carcinomas * SCLC not treated with the epirubicin-paclitaxel doublet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | through study completion, an average of 1 year | Time from epirubicin-paclitaxel regimen initiation to disease progression (according to Response Evaluation Criteria In Solid Tumors v1.1) or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 1 year | Time from epirubicin-paclitaxel regimen initiation to death from any cause |
| Objective response rate | 1 year | Complete response or partial response (according to Response Evaluation Criteria In Solid Tumors v1.1) |
| Disease control rate | 1 year | Objective response rate and stable disease (according to Response Evaluation Criteria In Solid Tumors v1.1) |
| Intracranial control rate | 1 year | Objective response rate and stable disease (according to Response Evaluation Criteria In Solid Tumors v1.1) |
| Toxicities | 1 year | According to Common Toxicity Criteria for Adverse Events version 5.0. |
Countries
France
Outcome results
None listed